

Remarks/arguments

Claims 1, 4-7, 21, 23-25, 29 and 38-41 are pending. Claims 2, 3, 8-20, 22, 26-28, and 30-37 have been cancelled. Claims 1, 4-6, 21, and 23-25 have been amended. Claims 1, 24, and 25 have been amended to recite “prostate or breast” cancer. Support for this amendment can be found in the specification at page 5, lines 11-17. Subject matter has been deleted from claims 1, 4-6, 21, and 23-25 in accordance with the Examiner’s suggestion (see below). New claim 41 has been added.

Rejection under 35 U.S.C. § 112, first paragraph, enablement

Claims 1, 4-7, 21, 23-25, 28, 29, and 38 have been rejected under 35 U.S.C. § 112, first paragraph, enablement. According to the Examiner, the specification enables treating breast cancer or prostate cancer by administering elected compound 41, but does not enable treating other cancers. The Examiner indicated that claims to a method of treating prostate or breast cancer comprising administering a compound of general formula (I) wherein R1, R2, R3, and R4 are independently selected from hydrogen, optionally substituted C₁₋₆-alkyl, or halogen; and X1 and X2 are independently selected from hydroxyl and acetoxy would be allowable. The claims have been so amended. Accordingly, applicants respectfully request that this rejection be withdrawn and the application passed to issue.


Application No.: 10/599,121

Conclusion

This application is believed to be in condition for allowance. If any issues remain which may be addressed by an Examiner's amendment or a supplemental amendment, the Examiner is respectfully requested to contact the undersigned.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Paul M. Zagar

Registration No. 52,392

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 212.547.5400 PMZ:MWE
Facsimile: 202.756.8087
Date: September 8, 2010

**Please recognize our Customer No. 20277
as our correspondence address.**